Lymphoma classification: The quiet after the storm

Seminars in Diagnostic Pathology

Volumn 28, Issue 2, 2011, Pages 113-123

  Pileri, Stefano A ^a   Agostinelli, Claudio ^a   Sabattini, Elena ^a   Bacci, Francesco ^a   Sagramoso, Carlo ^a   Pileri, Alessandro ^b   Falini, Brunangelo ^c   Piccaluga, Pier Paolo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Kiel classification; Lymphoma; Rappaport classification; WHO classification; Working formulation

Indexed keywords

ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER MORPHOLOGY; CARCINOGENESIS; CYTOGENETICS; EUROPE; GENE EXPRESSION PROFILING; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HIGH THROUGHPUT SEQUENCING; HISTIOCYTE; HUMAN; LYMPHATIC SYSTEM; LYMPHOMA; NATIONAL HEALTH ORGANIZATION; PHENOTYPE; PRIORITY JOURNAL; TREND STUDY; TUMOR DIFFERENTIATION; UNITED STATES;

HUMANS; LYMPHOMA; WORLD HEALTH ORGANIZATION;

EID: 79958006466     PISSN: 07402570     EISSN: 19301111     Source Type: Journal    
DOI: 10.1053/j.semdp.2011.02.001     Document Type: Article

References (91)

1. Rappaort H. Tumours of the hematopoietic system, in Atlas of Tumour Pathology, Sect 3, Fasc. 8 1966, Armed Forces Institute of Pathology, Washington, DC.
2. Lukes R.J., Collins R.D. Immunologic characterization of human malignant lymphomas. Cancer 1974, 34(suppl):1488-1503.
3. Lennert K. Malignant Lymphomas Other Than Hodgkin's Disease 1978, Springer Verlag, New York.
4. Stansfeld A.G., Diebold J., Noel H., et al. Updated Kiel Classification for lymphomas. Lancet 1988, 1:292-293.
5. Gerard-Marchant R., Hamlin I., Lennert K., et al. Classification of non-Hodgkin's lymphoma. Lancet 1974, 2:406.
6. Lennert K. Letter: Origin of malignant lymphomas. Lancet 1974, 2:586.
7. Higby D.J. A practical classification of lymphomas. N Engl J Med 1979, 300:1283.
8. Kay H.E. Letter: Classification of non-Hodgkin's lymphomas. Lancet 1974, 2:586.
9. Sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982, 49:2112-2135. National Cancer Institute.
10. Harris N.L., Jaffe E.S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392.
11. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17:3835-3849.
12. Jaffe E.S., Ralfkiaer E. Tumours of haematopoietic and lymphoid tissue. Pathology and Genetics 2001, 191-194. IARC Publishing Group, Lyon. E.S. Jaffe (Ed.).
13. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
14. Swerdlow S., Campo E., Harris N.L., et al. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues 2008, IARC, Lyon.
15. Vassallo J., Lamant L., Brugieres L., et al. ALK-positive anaplastic large cell lymphoma mimicking nodular sclerosis Hodgkin's lymphoma: Report of 10 cases. Am J Surg Pathol 2006, 30:223-229.
16. Falini B., Mecucci C., Tiacci E., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005, 352:254-266.
17. Cheng K., Sportoletti P., Ito K., et al. The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model. Blood 2010, 22:3341-3345.
18. Rau R., Brown P. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: Towards definition of a new leukaemia entity. Hematol Oncol 2009, 27:171-181.
19. Falini B., Martelli M.P., Mecucci C., et al. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice. Haematologica 2008, 93:775-779.
20. Chen W., Rassidakis G.Z., Medeiros L.J. Nucleophosmin gene mutations in acute myeloid leukemia. Arch Pathol Lab Med 2006, 130:1687-1692.
21. Falini B., Nicoletti I., Martelli M.F., et al. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): Biologic and clinical features. Blood 2007, 109:874-885.
22. Pasqualucci L., Liso A., Martelli M.P., et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. Blood 2006, 108:4146-4155.
23. Falini B., Martelli M.P., Bolli N., et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood 2006, 108:1999-2005.
24. Mariano A.R., Colombo E., Luzi L., et al. Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal. Oncogene 2006, 25:4376-4380.
25. Boissel N., Renneville A., Biggio V., et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005, 106:3618-3620.
26. Alcalay M., Tiacci E., Bergomas R., et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood 2005, 106:899-902.
27. Marti G.E., Rawstron A.C., Ghia P., et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol 2005, 130:325-332.
28. Rawstron A.C., Green M.J., Kuzmicki A., et al. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 2002, 100:635-639.
29. Burg G., Kempf W., Cozzio A., et al. WHO/EORTC classification of cutaneous lymphomas 2005: Histological and molecular aspects. J Cutan Pathol 2005, 32:647-674.
30. Khamaysi Z., Ben-Arieh Y., Izhak O.B., et al. The applicability of the new WHO-EORTC classification of primary cutaneous lymphomas to a single referral center. Am J Dermatopathol 2008, 30:37-44.
31. Piccaluga P.P., Califano A., Klein U., et al. Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas. Haematologica 2008, 93:1033-1038.
32. Finn L.S., Viswanatha D.S., Belasco J.B., et al. Primary follicular lymphoma of the testis in childhood. Cancer 1999, 85:1626-1635.
33. Lorsbach R.B., Shay-Seymore D., Moore J., et al. Clinicopathologic analysis of follicular lymphoma occurring in children. Blood 2002, 99:1959-1964.
34. Pinto A., Hutchison R.E., Grant L.H., et al. Follicular lymphomas in pediatric patients. Mod Pathol 1990, 3:308-313.
35. Swerdlow S.H. Pediatric follicular lymphomas, marginal zone lymphomas, and marginal zone hyperplasia. Am J Clin Pathol 2004, 122(suppl):S98-S109.
36. Misdraji J., Fernandez del Castillo C., Ferry J.A. Follicle center lymphoma of the ampulla of Vater presenting with jaundice: Report of a case. Am J Surg Pathol 1997, 21:484-488.
37. Sato Y., Ichimura K., Tanaka T., et al. Duodenal follicular lymphomas share common characteristics with mucosa-associated lymphoid tissue lymphomas. J Clin Pathol 2008, 61:377-381.
38. Shia J., Teruya-Feldstein J., Pan D., et al. Primary follicular lymphoma of the gastrointestinal tract: A clinical and pathologic study of 26 cases. Am J Surg Pathol 2002, 26:216-224.
39. Yoshino T., Miyake K., Ichimura K., et al. Increased incidence of follicular lymphoma in the duodenum. Am J Surg Pathol 2000, 24:688-693.
40. Ferry J.A., Fung C.Y., Zukerberg L., et al. Lymphoma of the ocular adnexa: A study of 353 cases. Am J Surg Pathol 2007, 31:170-184.
41. Bacon C.M., Diss T.C., Ye H., et al. Follicular lymphoma of the thyroid gland. Am J Surg Pathol 2009, 33:22-34.
42. Bacon C.M., Ye H., Diss T.C., et al. Primary follicular lymphoma of the testis and epididymis in adults. Am J Surg Pathol 2007, 31:1050-1058.
43. Cong P., Raffeld M., Teruya-Feldstein J., et al. In situ localization of follicular lymphoma: Description and analysis by laser capture microdissection. Blood 2002, 99:3376-3382.
44. Nodit L., Bahler D.W., Jacobs S.A., et al. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol 2003, 34:1030-1034.
45. Orchard J., Garand R., Davis Z., et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003, 101:4975-4981.
46. Richard P., Vassallo J., Valmary S., et al. "In situ-like" mantle cell lymphoma: A report of two cases. J Clin Pathol 2006, 59:995-996.
47. Fernàndez V., Salamero O., Espinet B., et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010, 15:1408-1418.
48. Oyama T., Yamamoto K., Asano N., et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: A study of 96 patients. Clin Cancer Res 2007, 13:5124-5132.
49. Park S., Lee J., Ko Y.H., et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007, 110:972-978.
50. Hummel M., Bentink S., Berger H., et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006, 354:2419-2430.
51. Chuang S.S., Ye H., Du M.Q., et al. Histopathology and immunohistochemistry in distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma with very high proliferation index and with or without a starry-sky pattern: A comparative study with EBER and FISH. Am J Clin Pathol 2007, 128:558-564.
52. Garcia J.F., Mollejo M., Fraga M., et al. Large B-cell lymphoma with Hodgkin's features. Histopathology 2005, 47:101-110.
53. Traverse-Glehen A., Pittaluga S., Gaulard P., et al. Mediastinal gray zone lymphoma: The missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol 2005, 29:1411-1421.
54. Rosenwald A., Wright G., Leroy K., et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003, 198:851-862.
55. Savage K.J., Monti S., Kutok J.L., et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003, 102:3871-3879.
56. Huang Y., Moreau A., Dupuis J., et al. Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am J Surg Pathol 2009, 33:682-690.
57. Matsumoto Y., Horiike S., Ohshiro M., et al. Expression of master regulators of helper T-cell differentiation in peripheral T-cell lymphoma, not otherwise specified, by immunohistochemical analysis. Am J Clin Pathol 2010, 133:281-290.
58. Rodriguez-Pinilla S.M., Atienza L., Murillo C., et al. Peripheral T-cell lymphoma with follicular T-cell markers. Am J Surg Pathol 2008, 32:1787-1799.
59. Benharroch D., Meguerian-Bedoyan Z., Lamant L., et al. ALK-positive lymphoma: A single disease with a broad spectrum of morphology. Blood 1998, 91:2076-2084.
60. Falini B., Bigerna B., Fizzotti M., et al. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol 1998, 153:875-886.
61. Pulford K., Lamant L., Espinos E., et al. The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci 2004, 61:2939-2953.
62. Stein H., Foss H.D., Durkop H., et al. CD30(+) anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features. Blood 2000, 96:3681-3695.
63. Gascoyne R.D., Aoun P., Wu D., et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999, 93:3913-3921.
64. Shiota M., Nakamura S., Ichinohasama R., et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: A distinct clinicopathologic entity. Blood 1995, 86:1954-1960.
65. Savage K.J., Harris N.L., Vose J.M., et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood 2008, 111:5496-5504.
66. Piva R., Agnelli L., Pellegrino E., et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J Clin Oncol 2010, 20:1583-1590.
67. Piccaluga P.P., Agostinelli C., Califano A., et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 2007, 117:823-834.
68. Van Overbeke L., Ectors N., Tack J. What is the role of celiac disease in enteropathy-type intestinal lymphoma?. A retrospective study of nine cases. Acta Gastroenterol Belg 2005, 68:419-423.
69. +CD5-T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol 1998, 153:1483-1490.
70. Chott A., Vesely M., Simonitsch I., et al. Classification of intestinal T-cell neoplasms and their differential diagnosis. Am J Clin Pathol 1999, 111:S68-S74.
71. Deleeuw R.J., Zettl A., Klinker E., et al. Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology 2007, 132:1902-1911.
72. Toro J.R., Liewehr D.J., Pabby N., et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 2003, 101:3407-3412.
73. Willemze R., Jansen P.M., Cerroni L., et al. Subcutaneous panniculitis-like T-cell lymphoma: Definition, classification, and prognostic factors: An EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 2008, 111:838-845.
74. Kumar S., Krenacs L., Medeiros J., et al. Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes. Hum Pathol 1998, 29:397-403.
75. Quintanilla-Martinez L., Kumar S., Fend F., et al. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: A distinct clinicopathologic syndrome. Blood 2000, 96:443-451.
76. Barrionuevo C., Anderson V.M., Zevallos-Giampietri E., et al. Hydroa-like cutaneous T-cell lymphoma: A clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol 2002, 10:7-14.
77. Rabbani G.R., Phyliky R.L., Tefferi A. A long-term study of patients with chronic natural killer cell lymphocytosis. Br J Haematol 1999, 106:960-966.
78. Berti E., Tomasini D., Vermeer M.H., et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol 1999, 155:483-492.
79. Bekkenk M.W., Vermeer M.H., Jansen P.M., et al. Peripheral T-cell lymphomas unspecified presenting in the skin: Analysis of prognostic factors in a group of 82 patients. Blood 2003, 102:2213-2219.
80. Garcia-Herrera A., Colomo L., Camós M., et al. Primary cutaneous small/medium CD4+ T-cell lymphomas: A heterogeneous group of tumors with different clinicopathologic features and outcome. J Clin Oncol 2008, 26:3364-3371.
81. Summers K.E., Goff L.K., Wilson A.G., et al. Frequency of the Bcl-2/IgH rearrangement in normal individuals: Implications for the monitoring of disease in patients with follicular lymphoma. J Clin Oncol 2001, 19:420-424.
82. Zignego A.L., Ferri C., Giannelli F., et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 2002, 137:571-580.
83. Lecluse Y., Lebailly P., Roulland S., et al. t(11;14)-Positive clones can persist over a long period of time in the peripheral blood of healthy individuals. Leukemia 2009, 23:1190-1193.
84. Gisselbrecht C., Gaulard P., Lepage E., et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998, 92:76-82.
85. Gallamini A., Stelitano C., Calvi R., et al. Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study. Blood 2004, 103:2474-2479.
86. Evens A.M., Gartenhaus R.B. Treatment of T-cell non-Hodgkin's lymphoma. Curr Treat Options Oncol 2004, 5:289-303.
87. Vose J., Armitage J., Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 2008, 26:4124-4130.
88. Martinez-Delgado B., Cuadros M., Honrado E., et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia 2005, 19:2254-2263.
89. Piva R., Chiarle R., Manazza A.D., et al. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood 2006, 107:689-697.
90. Chiarle R., Voena C., Ambrogio C., et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008, 8:11-23.
91. Chiarle R., Simmons W.J., Cai H., et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005, 11:623-629.